Ayan Kumar Barui

Ayan Kumar Barui

Auto-generated profile, based on publicly available information

Ayan Kumar Barui

Department of Chemistry, Ulsan National Institute of Science and Technology, Ulsan 44919, Republic of Korea

Research Focus & Metrics

Academic Career Length

15Years (2012-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 August 2015 in Materials Science and Engineering: C
Verified
Journal Article
Closed access
SPSujata Patra
Sujata Patra
SMSudip Mukherjee
Sudip Mukherjee
ABAyan Kumar Barui
Ayan Kumar Barui
AGAnirban Ganguly
Anirban Ganguly
BSBojja Sreedhar
Bojja Sreedhar
CPChittaranjan Patra
Chittaranjan Patra

1 June 2015 in Advanced Healthcare Materials
Verified
Journal Article
Closed access
PDF file
SMSudip Mukherjee
Sudip Mukherjee
PSPavithra Sriram
Pavithra Sriram
ABAyan Kumar Barui
Ayan Kumar Barui
SNSusheel Kumar Nethi
Susheel Kumar Nethi
VVVimal Veeriah
Vimal Veeriah
CPChittaranjan Patra
Chittaranjan Patra

12 October 2012 in Nanotechnology
Verified
Journal Article
Closed access
SMSudip Mukherjee
Sudip Mukherjee
VSV Sushma
V Sushma
SPSujata Patra
Sujata Patra
ABAyan Kumar Barui
Ayan Kumar Barui
MBManika Pal Bhadra
Manika Pal Bhadra
CPChitta Ranjan Patra
Chitta Ranjan Patra
The biological approach to synthesis of AuNPs is eco-friendly and an ideal method to develop environmentally sustainable nanoparticles alternative to existing methods. We have developed a simple, fast, clean, efficient, low-cost and eco-friendly single-step green chemistry approach for the synthesis of biocompatible gold nanoparticles (AuNPs) from chloroauric acid (HAuCl(4)) using a water extract of Eclipta Alba leaves at room temperature. The AuNPs using Eclipta extract have been formed in very short time, even in less than 10 min. The as-synthesized AuNPs were thoroughly characterized by several physico-chemical techniques. The in vitro stability of as-synthesized AuNPs was studied in different buffer solutions. A plausible mechanism for the synthesis of AuNPs by Eclipta extract has been discussed. The biocompatibility of AuNPs was observed by in vitro cell culture assays. Finally, we have designed and developed a AuNPs-based drug delivery system (DDS) (Au-DOX) containing doxorubicin (DOX), a FDA approved anticancer drug. Administration of this DDS to breast cancer cells (MCF-7 and MDA-MB-231) shows significant inhibition of breast cancer cell proliferation compared to pristine doxorubicin. Therefore we strongly believe that the use of Eclipta Alba offers large-scale production of biocompatible AuNPs that can be used as a delivery vehicle for the treatment of cancer diseases.

23 October 2012 in Nanoscale
Verified
Journal Article
Closed access
PDF file
ABAyan Kumar Barui
Ayan Kumar Barui
VVVimal Veeriah
Vimal Veeriah
SMSudip Mukherjee
Sudip Mukherjee
JMJoydeb Manna
Joydeb Manna
APAjay Kumar Patel
Ajay Kumar Patel
CPChittaranjan Patra
Chittaranjan Patra
It is well established that angiogenesis is the process of formation of new capillaries from pre-existing blood vessels. It is a complex process, involving both pro- and anti-angiogenic factors, and plays a significant role in physiological and pathophysiological processes such as embryonic development, atherosclerosis, post-ischemic vascularization of the myocardium, tumor growth and metastasis, rheumatoid arthritis etc. This is the first report of zinc oxide (ZnO) nanoflowers that show significant pro-angiogenic properties (formation of new capillaries from pre-existing blood vessels), observed by in vitro and in vivo angiogenesis assays. The egg yolk angiogenesis assay using ZnO nanoflowers indicates the presence of matured blood vessels formation. Additionally, it helps to promote endothelial cell (EA.hy926 cells) migration in wound healing assays. Formation of reactive oxygen species (ROS), especially hydrogen peroxide (H2O2)—a redox signaling molecule, might be the plausible mechanism for nanoflower-based angiogenesis. Angiogenesis by nanoflowers may provide the basis for the future development of new alternative therapeutic treatment strategies for cardiovascular and ischemic diseases, where angiogenesis plays a significant role.

16 December 2015 in Biomaterials Science
Verified
Journal Article
Closed access
PDF file
RKRajesh Kotcherlakota
Rajesh Kotcherlakota
ABAyan Kumar Barui
Ayan Kumar Barui
SPSanjiv Prashar
Sanjiv Prashar
MFMariano Fajardo
Mariano Fajardo
DBDavid Briones
David Briones
Santiago Gomez-RuizSantiago Gomez-Ruiz
Santiago Gomez-Ruiz
In the present study, we report the delivery of anti-cancer drug curcumin to cancer cells using mesoporous silica materials. A series of mesoporous silica material based drug delivery systems (S2, S4 and S6) were first designed and developed through the amine functionalization of KIT-6, MSU-2 and MCM-41 followed by the loading of curcumin. The curcumin loaded materials were characterized with several physico-chemical techniques and thoroughly screened on cancer cells to evaluate their in vitro drug delivery efficacy. All the curcumin loaded silica materials exhibited higher cellular uptake and inhibition of cancer cell viability compared to pristine curcumin. The effective internalization of curcumin in cancer cells through the mesoporous silica materials initiated the generation of intracellular reactive oxygen species and the down regulation of poly ADP ribose polymerase (PARP) enzyme levels compared to free curcumin leading to the activation of apoptosis. This study shows that the anti-cancer activity of curcumin can be potentiated by loading onto mesoporous silica materials. Therefore, we strongly believe that mesoporous silica based curcumin loaded drug delivery systems may have future potential applications for the treatment of cancers.

20 April 2015 in PLOS ONE
Verified
Journal Article
Open access
PDF file
RARamu Adela
Ramu Adela
SNSusheel Kumar Nethi
Susheel Kumar Nethi
PBPankaj K. Bagul
Pankaj K. Bagul
ABAyan K. Barui
Ayan K. Barui
SMSaidulu Mattapally
Saidulu Mattapally
SBSanjay Banerjee
Sanjay Banerjee
We have previously reported that increased glucose levels were associated with higher serum nitric oxide (NO) levels in fructose-fed insulin resistant rats. However, the relationship between hyperglycemia and serum NO level was not clear. Therefore, the present study was designed to find the association between hyperglycemia and serum NO levels in Type 2 diabetic (T2DM) patients and T2DM with cardiovascular complication. Endothelial cells (HUVEC) were treated with of D-glucose (10-100mM), and NO levels and NOS gene expression was measured. Hyperglycaemia was induced in Sprague-Dawley rats, and serum NO levels were measured after 8 weeks. For clinical evaluation, five groups of patients were recruited: Control (CT, n=48), Type 2 diabetes (T2DM, n=26), T2DM with hypertension (DMHT, n=46), Coronary artery diseases (CAD, n=29) and T2DM with coronary artery diseases (DMCD, n=38). NO (nitrite + nitrate) levels were measured from human serum. We found a significant (p<0.05) and dose-dependent increase in NO levels in HUVEC cells after 4 hours of high glucose exposure. eNOS and iNOS gene expression was increased in HUVEC cells after different concentrations and time periods of glucose treatment. We also observed significant (149.1±25μM, p<0.01) increase in serum NO levels in hyperglycaemic rats compared to control (76.6±13.2μM). Serum NO level was significantly higher in T2DM (111.8 μM (81.7-122.4), p<0.001) and DMCD patients ((129.4 μM (121.2-143.5), p <0.001) but not in CAD patients (76.4 μM (70.5-87)), as compared to control (68.2 μM (56.4-82.3)). We found significantly lower NO levels (83.5 μM (60.5-122.9)) in subjects suffering from diabetes since more than 5 years, compared to subjects (115.3 μM (75.2-127.1), p<0.001) with less than 5 years. In conclusion, high NO levels were observed in South Indian diabetic patients. Higher glucose levels in serum might be responsible for activation of endothelial cells to enhance NO levels.